Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
SanBio Co Ltd (SanBio) carries out the business of development, production and sales of regenerative cell medicines. The company offers pipeline products such as SB623 which treats traumatic brain injury, dry age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, spinal cord injury, Alzheimer’s disease, ischemic stroke and hemorrhagic stroke; SB618 targets peripheral nerve damage and others; SB308 for muscle dystrophy; MSC1 which targets cancer; MSC2 which treats inflammatory disease and optic neuritis. It has operations across the US and Japan. SanBio is headquartered in Chuo-ku, Tokyo, Japan.
Headquarters
Japan
Address
13f, St. Luke Tower, 8-1, Akashi-Cho, Chuo-Ku, Tokyo, 104-0044
Website
www.sanbio.com
Telephone
81 3 62643481
No of Employees
33
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4592 (TYO)
EPS
XYZ
Net Income (2025)
XYZ
-33.3%
(2025 vs 2024)
Market Cap*
$488.0M
Net Profit Margin (0 vs)
XYZ
0.0%
(2025 vs 2024)
* As of and is in US$
SanBio Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Akuugo |
| SB623: | |
| Chronic Ischemic Stroke | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | SanBio Co Ltd | Kidswell Bio Corp | AnGes Inc | Healios KK | CellSeed Inc |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Ibaraki | Chiyoda-Ku | Koto-Ku |
| State/Province | Tokyo | Tokyo | Osaka | Tokyo | Tokyo |
| No. of Employees | 33 | 37 | 56 | 75 | 36 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Toru Kawanishi | Chairman | Executive Board | - | - |
| Keita Mori | Director; President | Executive Board | - | - |
| Shinya Hirata | Corporate Officer; Head - Research and Development | Senior Management | - | - |
| Soyoku Nobeyama | Corporate Officer; Head - Regulatory Affairs and Quality Compliance - Japan | Senior Management | 2025 | - |
| Naoki Tsukahara | Senior Corporate Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer